Abstract
Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIRs and HLA loci are highly polymorphic, and some of their combinations have been found to protect against viral infections or to predispose to autoimmune disorders. In particular, some activating KIRs profiles may be detrimental in autoimmune pathogenesis, and specific KIRs may be particularly aggressive in the clearance of different microorganisms, protecting individuals in the control of a given pathogen. So, considering that in the pathogenesis of many autoimmune disorders and infections innate immunity plays a key role, the recent development for KIRs characterization, diseases monitoring, and treatment becomes obvious. Here, we reviewed a growing body of evidence supporting the influence of KIRs variants and their interaction with ligands in the development of the main human autoimmune and viral diseases, highlighting the main applications in clinical practice.
Keywords: Autoimmune diseases, HLA ligands, immunogenetics, KIRs, translational medicine, viral infections.
Current Pharmaceutical Design
Title:Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases
Volume: 24 Issue: 26
Author(s): Anna Aiello*, Giuseppina Candore*, Giulia Accardi, Calogero Caruso, Claudia Colomba, Giovanni Duro, Caterina Maria Gambino, Mattia Emanuela Ligotti and Danilo Di Bona
Affiliation:
- University of Palermo, Department of Pathobiology and Medical Biotechnologies, Section of General Pathology, Corso Tukory 211, 90134, Palermo,Italy
- University of Palermo, Department of Pathobiology and Medical Biotechnologies, Section of General Pathology, Corso Tukory 211, 90134, Palermo,Italy
Keywords: Autoimmune diseases, HLA ligands, immunogenetics, KIRs, translational medicine, viral infections.
Abstract: Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIRs and HLA loci are highly polymorphic, and some of their combinations have been found to protect against viral infections or to predispose to autoimmune disorders. In particular, some activating KIRs profiles may be detrimental in autoimmune pathogenesis, and specific KIRs may be particularly aggressive in the clearance of different microorganisms, protecting individuals in the control of a given pathogen. So, considering that in the pathogenesis of many autoimmune disorders and infections innate immunity plays a key role, the recent development for KIRs characterization, diseases monitoring, and treatment becomes obvious. Here, we reviewed a growing body of evidence supporting the influence of KIRs variants and their interaction with ligands in the development of the main human autoimmune and viral diseases, highlighting the main applications in clinical practice.
Export Options
About this article
Cite this article as:
Aiello Anna *, Candore Giuseppina*, Accardi Giulia , Caruso Calogero , Colomba Claudia , Duro Giovanni , Gambino Maria Caterina , Ligotti Emanuela Mattia and Di Bona Danilo , Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases, Current Pharmaceutical Design 2018; 24 (26) . https://dx.doi.org/10.2174/1381612824666180911123249
DOI https://dx.doi.org/10.2174/1381612824666180911123249 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies Against Parasitic Protozoa
Current Pharmaceutical Design Current and Emerging Strategies in Osteoporosis Management
Current Pharmaceutical Design Integral Therapeutic Potential of Bone Marrow Mesenchymal Stem Cells
Current Drug Targets Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Cytokines in the Central Nervous System: Targets for Therapeutic Intervention
Current Drug Targets - CNS & Neurological Disorders Aerosol Delivery Devices for the Treatment of Adult Patients in Acute and Critical Care
Current Pharmaceutical Biotechnology Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Molluscum Contagiosum: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Current Pharmaceutical Design Heme Oxygenase-1: A Fundamental Guardian Against Oxidative Tissue Injuries in Acute Inflammation
Mini-Reviews in Medicinal Chemistry Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials
Reviews on Recent Clinical Trials New Drug Targets for Hepatitis C and Other Flaviviridae Viruses
Infectious Disorders - Drug Targets Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Current Medicinal Chemistry The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism